Sign up to save your podcasts
Or
Share Episode 55: Alnylam
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Episode 55: Alnylam
Send us Fan Mail
From the discovery of RNA interference to the first FDA-approved gene-silencing therapy, this week on Petri Dish Perspectives, we dive into the story of Alnylam Pharmaceuticals, the company that turned one of biology’s most powerful mechanisms into an entirely new class of medicine.
We explore the science behind RNAi, the delivery challenges that nearly killed the field, the leadership of John Maraganore, and how partnerships with Novartis, Sanofi, Regeneron Pharmaceuticals, and Roche helped transform Alnylam from a risky platform biotech into a genetic medicines powerhouse. We also break down the development of Onpattro, Amvuttra, and the broader future of programmable medicine.
This is the story of persistence, platform biology, and the rise of RNA therapeutics.
🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday!
https://linktr.ee/maneadkhin
#Biotech #Alnylam #RNAi #GeneticMedicine #Biopharma #RNAInterference #Onpattro #Amvuttra #RareDisease #DrugDevelopment #PrecisionMedicine #Biotechnology #HealthcareInnovation #Pharma #PetriDishPerspectives
Support the show
© 2026 The Perspective Bureau LLC. All rights reserved.
View all episodes
By Manead KhinSend us Fan Mail
From the discovery of RNA interference to the first FDA-approved gene-silencing therapy, this week on Petri Dish Perspectives, we dive into the story of Alnylam Pharmaceuticals, the company that turned one of biology’s most powerful mechanisms into an entirely new class of medicine.
We explore the science behind RNAi, the delivery challenges that nearly killed the field, the leadership of John Maraganore, and how partnerships with Novartis, Sanofi, Regeneron Pharmaceuticals, and Roche helped transform Alnylam from a risky platform biotech into a genetic medicines powerhouse. We also break down the development of Onpattro, Amvuttra, and the broader future of programmable medicine.
This is the story of persistence, platform biology, and the rise of RNA therapeutics.
🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday!
https://linktr.ee/maneadkhin
#Biotech #Alnylam #RNAi #GeneticMedicine #Biopharma #RNAInterference #Onpattro #Amvuttra #RareDisease #DrugDevelopment #PrecisionMedicine #Biotechnology #HealthcareInnovation #Pharma #PetriDishPerspectives
Support the show
© 2026 The Perspective Bureau LLC. All rights reserved.